Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study
Cheng F et al. BMC Cancer, February 2026 (epub ahead of print) – open access publication
Link to full abstract